Iovance Biotherapeutics to Host Conference Call to Discuss Third Quarter 2017 Financial Results and Provide a Corporate Updat...
25 October 2017 - 11:00PM
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology
company developing novel cancer immunotherapies based on
tumor-infiltrating lymphocyte (TIL) technology, today
announced that it will report its third quarter 2017 financial and
operating results after the close of the U.S. financial markets on
Tuesday, October 31, 2017. Management will host a conference call
and live audio webcast to discuss these results and provide a
corporate update at 4:30 p.m. ET.
In order to participate in the conference call, please dial
1-844-646-4465 (domestic) or 1-615-247-0257 (international) and
reference the access code 1423064. The live webcast can be accessed
under “News & Events” in the “Investors” section of the
Company’s website at http://www.iovance.com/ or you may use the
link: https://edge.media-server.com/m6/p/q7762k6j.
A replay of the call will be available from October 31, 2017 at
7:00 p.m. ET to November 30, 2017 at 8:30 p.m. ET. To access the
replay, please dial 1-855-859-2056 (domestic) or 1-404-537-3406
(international) and reference the access code 1423064. The archived
webcast will be available for thirty days in the Investors section
of Iovance Biotherapeutics’ website at http://www.iovance.com/.
About Iovance Biotherapeutics, Inc.Iovance
Biotherapeutics, Inc. is a clinical-stage biotechnology
company focused on the development of cancer immunotherapy products
for the treatment of various cancers. The Company's lead product
candidate is an adoptive cell therapy using tumor-infiltrating
lymphocyte (TIL) technology being investigated for the treatment of
patients with metastatic melanoma, recurrent and/or metastatic
squamous cell carcinoma of the head and neck and recurrent and
metastatic or persistent cervical cancer. For more information,
please visit http://www.iovance.com.
Investor Contact: Sarah McCabeStern Investor
Relations, Inc.212-362-1200sarah@sternir.com
Media Contact:Evan Smith/Kotaro YoshidaFTI
Consulting212-850-5622/212-850-5690
evan.smith@fticonsulting.comkotaro.yoshida@fticonsulting.com
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Apr 2024 to May 2024
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From May 2023 to May 2024